TransMedics Group, Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: TransMedics Group, Inc. |
Ticker: | Ticker: TMDX |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On January 10, 2025, Scorpion Capital released an investigation report alleging wrongdoing in TransMedics’ business practices, including fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The report also highlighted ongoing regulatory scrutiny, with reports of investigation by the DOJ, IRS, and state attorneys general into Medicare fraud linked to organ acquisition costs. Additionally, the report made claims regarding customer dissatisfaction, with prominent transplant centers discontinuing their use of TransMedics devices and citing concerns over clinical value. On this news, the price of TransMedics shares declined by $3.74 per share, from $72.55 per share on January 8, 2025, to close at $68.81 on January 10, 2025.
On January 10, 2025, Scorpion Capital released an investigation report alleging wrongdoing in TransMedics’ business practices, including fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The report also highlighted ongoing regulatory scrutiny, with reports of investigation by the DOJ, IRS, and state attorneys general into Medicare fraud linked to organ acquisition costs. Additionally, the report made claims regarding customer dissatisfaction, with prominent transplant centers discontinuing their use of TransMedics devices and citing concerns over clinical value. On this news, the price of TransMedics shares declined by $3.74 per share, from $72.55 per share on January 8, 2025, to close at $68.81 on January 10, 2025.